Materiały źródłowe

• #1 Oligodendroglioma | Treatment & Management | Point of Care

  https://www.statpearls.com/point-of-care/26152

  OGs are uncommon, with an incidence of 0.2 per 100,000 people, and are the third most common primary brain neoplasm following the glioblastoma and the diffuse astrocytoma. OGs comprise approximately 5% of all primary CNS tumors. […] These tumors have a slight male predominance, reported from 1.1 to 2, with as low as a 0.92 male-to-female ratio, as seen from the results of a study. OGs have a slight bimodal distribution but are primarily adult neoplasm, with a peak incidence occurring in the fourth and fifth decades and a smaller tumor incidence peak in children aged 6 to 12. […] OGs in pediatric patients usually demonstrate different molecular markers than are seen in the adult form, raising the issue of whether they represent the same neoplasm.

• #1 Oligodendroglioma epidemiology and demographics – wikidoc

  https://www.wikidoc.org/index.php/Oligodendroglioma_epidemiology_and_demographics

  Oligodendroglioma, although rare, is the third most common glioma. In adults, it constitutes about 9.4% of all primary brain and central nervous system tumors and 5%18% of all glial neoplasms. The incidence of oligodendroglioma and anaplastic oligodendroglioma is estimated to be 0.32 and 0.17 cases per 100,000 individuals in the United States, respectively. Oligodendroglioma tends to affect the middle-aged adult population, most commonly occurring in the 4th and 5th decade of life. Median age at the time of diagnosis of oligodendroglioma is 35-47 years. Males are more commonly affected with oligodendroglioma than females with male to female ratio being approximately 1.3:1. Oligodendroglioma usually affects individuals of the Caucasian race. African American, Latin American, and Asian individuals are less likely to develop oligodendroglioma.

• #1 Oligodendroglioma epidemiology and demographics – wikidoc

  https://www.wikidoc.org/index.php/Oligodendroglioma_epidemiology_and_demographics

  Oligodendroglioma, although rare, is the third most common glioma. It occurs primarily in adults constituting about 9.4% of all primary brain and central nervous system tumors and 5%18% of all glial neoplasms. […] Incidence of oligodendroglioma and anaplastic oligodendroglioma is estimated to be 0.32 and 0.17 cases per 100,000 individuals in the United States, respectively. Approximately, 1000 oligodendroglial tumors are diagnosed each year in United States. […] Oligodendroglioma is a disease that tends to affect the middle-aged adult population (adults between 25 and 45 years of age). Oligodendroglioma most commonly occurs in the 4th and 5th decade of life. Median age at diagnosis of oligodendroglioma is 35-47 years. Median age at diagnosis is approximately 5 to 10 years older for World Health Organization (WHO) grade III (anaplastic) tumors compared with WHO grade II (low-grade) tumors. Oligodendroglioma is occasionally diagnosed in teenagers and in adults over the age of 65 years. […] Males are more commonly affected with oligodendroglioma than females. The male to female ratio is approximately 1.3:1. […] Oligodendroglioma usually affects individuals of the Caucasian race. African American, Latin American, and Asian individuals are less likely to develop oligodendroglioma.

• #1 Clinical features, diagnosis, and pathology of IDH-mutant, 1p/19q-codeleted oligodendrogliomas – UpToDate

  https://www.uptodate.com/contents/clinical-features-diagnosis-and-pathology-of-idh-mutant-1p-19q-codeleted-oligodendrogliomas

  Oligodendroglial tumors are rare tumors, constituting approximately 5 percent of all malignant primary tumors of the central nervous system. Together, grade 2 and 3 oligodendrogliomas are one-tenth as common as glioblastoma, the most commonly occurring malignant primary brain tumor in adults. Approximately 1000 oligodendroglial tumors are diagnosed in the United States each year, with an age-adjusted incidence of 0.27 per 100,000 people. […] Environmental and genetic risk factors for primary brain tumors are reviewed separately.

• #1 Oligodendroglioma and Other IDH-Mutated Tumors: Diagnosis and Treatment – NCI

  https://www.cancer.gov/rare-brain-spine-tumor/tumors/oligodendroglioma

  Oligodendrogliomas occur in people of any age but are most common in those between the ages of 35 and 44. They occur more often in males and are rare in children. They are most common in non-Hispanic white people. An estimated 14,950 people are living with this tumor in the United States. […] The relative five-year survival rate for oligodendroglioma is 79.5 percent. However, many factors affect prognosis. These include the tumor grade and molecular type, the persons age and health when diagnosed, and how they respond to treatment. If you want to understand your prognosis, talk to your doctor.

• #1 Oligodendroglioma – VALINTERMED treatment in Valencia

  https://valintermed.com/en/medlibrary/oligodendroglioma-2/

  According to statistics, oligodendrogliomas account for about 5-10% of all gliomas and 1-2% of all brain tumors. These tumors are most common in adults aged 30 to 50 years and are slightly more common in men than in women. According to the journal Neuro-Oncology, the incidence of oligodendrogliomas in the United States is 0.4-0.5 cases per 100,000 people per year. In European countries, the rates are similar. It is also noted that oligodendrogliomas are more often diagnosed in people with a genetic predisposition, in particular, in those who have hereditary syndromes, including Li-Fraumeni syndrome and neurofibromatosis type 2. […] Monitoring of patients with oligodendrogliomas includes regular follow-up examinations with MRI to assess possible disease progression or recurrence. Prognosis depends on a number of factors, including the grade of malignancy and the presence of specific genetic mutations. In general, 5-year survival for low-grade oligodendrogliomas is up to 80%, while for high-grade forms it is lower and is about 20-30%. Complications after treatment may include neurological deficits and adverse reactions to chemotherapy, which requires careful rehabilitation.

• #1 Orphanet: Oligodendroglial tumor

  https://www.orpha.net/en/disease/detail/46484

  Oligodendrogliomas may represent up to 30% of all adult gliomas. Annual incidence can therefore be estimated at around one new case per 100,000 individuals per year. Prevalence is estimated at 1/300,000. […] Until now, the incidence of these tumors has been largely underestimated.

• #1 Oligodendroglioma – Symptoms, Diagnosis, TreatmentSecond Opinion IconGroup 9Second Opinion IconGroup 49

  https://www.barrowneuro.org/condition/oligodendroglioma/

  Oligodendrogliomas account for less than two percent of brain tumors in the U.S., with approximately 1,100 new diagnoses each year. […] As of 2023, an estimated 15,000 people live with an oligodendroglioma in the U.S. […] While rare, oligodendrogliomas are more commonly diagnosed in adults and occur slightly more often in men than in women. […] Doctors diagnose most oligodendrogliomas in adults between 30 and 50. […] The average age at diagnosis for Grade 2 oligodendrogliomas is 43, and for Grade 3 oligodendrogliomas, it is 50. […] Most oligodendrogliomas are not inherited, but a family history of brain tumors or gliomas can slightly increase the overall risk. […] With regular treatment and monitoring, many people with oligodendrogliomas can live for years or even decades, especially those with low-grade tumors or favorable genetic markers.

• #1 Surgery Insight: The Role of Surgery in the Management of Low-Grade Gliomas

  https://www.medscape.org/viewarticle/564764_2

  Low-grade gliomas are particularly prevalent among white people and among men, and the highest incidence is in people between 35 and 44 years of age. […] Oligodendrogliomas are most commonly seen along the cerebral convexity in subcortical areas, particularly in the frontal lobe, but sporadic reports of posterior fossa oligodendrogliomas exist.

• #1 Oligodendrogliomas in pediatric and adult patients: an outcome-based study from the Surveillance, Epidemiology, and End Result database

  https://pmc.ncbi.nlm.nih.gov/articles/PMC5422333/

  Oligodendrogliomas (OGs) account for 20% of all intracranial tumors and 25% of gliomas. […] Data on 7,001 OG patients were abstracted from the Surveillance, Epidemiology, and End Result (SEER) database (19732013). […] Among 7,001 OG patients, 6.5% were pediatric (mean age 12 6 years), and 93.5% were adult (mean age 46 15 years). […] Overall, OGs were more common among males, with a male-to-female ratio of 1.28:1. […] Overall, OGs were more common among Caucasians (76.9%) and also among the African American (10.8% pediatric vs. 4.0% adult) and Hispanic (12.8% pediatric vs. 11.8% adult). […] Surgical resection was the primary treatment modality for both pediatric and adult populations (70.6% and 40.5%), followed by combined surgery and radiation (19.7% and 41.2%). […] Surgical resection was associated with significantly improved survival in both groups.

• #1 Oligodendroglioma: Symptoms, Treatment & Prognosis

  https://my.clevelandclinic.org/health/diseases/21191-oligodendroglioma

  Oligodendrogliomas account for between 5% and 15% of all gliomas, and about 3% to 4% of all brain tumors. Worldwide, healthcare providers diagnose just under 24,000 people with oligodendroglioma each year. Most people who have it are between the ages of 40 and 50. […] Researchers haven’t confirmed any risk factors for oligodendroglioma. But there’s research that could mean past radiation therapy (like the type used to treat other cancers) is a possible factor for developing similar tumors called gliomas. More research is necessary to confirm if that could be a cause or contributing factor. […] Oligodendrogliomas are among the more treatable brain tumors and cancers. The treatment often involves multiple methods, including surgery, chemotherapy, and radiation therapy. […] Oligodendrogliomas are treatable, but not technically curable, tumors. The most likely approach to treating oligodendroglioma is to remove the whole tumor (or as much of it as possible) and then your care team determines if chemotherapy, radiation therapy or a combination of these are necessary to eradicate any remaining cancer cells.

• #1 Oligodendroglioma overview – wikidoc

  https://www.wikidoc.org/index.php/Oligodendroglioma_overview

  Oligodendroglioma, although rare, is the third most common glioma. In adults, it constitutes about 9.4% of all primary brain and central nervous system tumors and 5%18% of all glial neoplasms. The incidence of oligodendroglioma and anaplastic oligodendroglioma is estimated to be 0.32 and 0.17 cases per 100,000 individuals in the United States, respectively. Oligodendroglioma tends to affect the middle-aged adult population, most commonly occurring in the 4th and 5th decade of life. Median age at the time of diagnosis of oligodendroglioma is 35-47 years. Males are more commonly affected with oligodendroglioma than females with male to female ratio being approximately 1.3:1. Oligodendroglioma usually affects individuals of the Caucasian race. African American, Latin American, and Asian individuals are less likely to develop oligodendroglioma. […] The most potent risk factor for the development of oligodendroglioma is a positive family history of brain tumors. […] There is insufficient evidence for recommending routine screening for oligodendroglioma.

• #1 Oligodendroglioma | MedLink Neurology

  https://www.medlink.com/articles/oligodendroglioma

  Oligodendrogliomas are relatively rare. According to the Central Brain Tumor Registry of the United States (CBTRUS), the average age-adjusted annual incidence rate of oligodendroglioma is 0.30 for adults 40 years or older. Oligodendroglioma is rarer in children: the annual average age-adjusted incidence rate for patients younger than 15 years of age is 0.02% compared to 0.26% for patients aged 15 to 39 years. No patients younger than 40 years with oligodendroglioma WHO grade 3 were documented from 2016 to 2020 (44). It is highly likely that these epidemiologic numbers may shift as our registries catch up to the rapid changes observed in molecular neuropathology and their associated impact on the WHO classification system. […] Risk factors for glioma include inheritable genetic syndromes (such as Li-Fraumini, neurofibromatosis type 1, and Maffucci syndrome) and exposure to high-dose ionizing radiation, though no risk factors specific for oligodendroglioma are known; thus, no known preventative measures have been identified (38; 02).

• #1 Oligodendroglioma – Symptoms, Diagnosis, TreatmentSecond Opinion IconGroup 9Second Opinion IconGroup 49

  https://www.barrowneuro.org/condition/oligodendroglioma/

  As a whole, the five-year survival rate for oligodendrogliomas is 79.5 percent. […] For Grade 2 oligodendrogliomas, the five- to 10-year survival rate can be as high as 90 percent with optimal treatment and ideal genetic factors. […] The prognosis for Grade 3 oligodendrogliomas varies more, with five-year survival rates between 30 and 50 percent, depending on the response to treatment and genetic factors. […] Currently, there is no known way to prevent oligodendrogliomas from developing. […] Some cases are linked to rare genetic conditions, like neurofibromatosis type I (NF1) and Li-Fraumeni Syndrome, which increases the risk of some brain tumors, including oligodendrogliomas. […] Advances in genetic research may one day help identify additional oligodendroglioma risk factors.

• #1 Oligodendroglioma – American Brain Tumor Association | Learn More

  https://www.abta.org/tumor_types/oligodendroglioma/

  Oligodendrogliomas are estimated to account for 1.3% of brain tumors in the United States with approximately 1,100 new diagnoses in the United States each year. […] Oligodendrogliomas are most common in adults and most often occur between the ages of 20-40. Although these tumors are found in both men and women, they tend to occur more often in men. Oligodendrogliomas are very rare in children under the age of 15. […] Regular MRI scans are recommended following the diagnosis of oligodendroglioma, generally at least once per year. Patients with seizures will need to be followed for their seizure medication.

• #1 Oligodendroglioma | Canadian Cancer Society

  https://cancer.ca/en/cancer-information/cancer-types/brain-and-spinal-cord/what-is-a-brain-or-spinal-cord-tumour/oligodendroglioma

  Oligodendrogliomas are a type of glioma that starts in glial cells called oligodendrocytes. Oligodendroglioma sometimes spreads to the cerebrospinal fluid but rarely spreads outside the brain or spinal cord. Based on the World Health Organization (WHO) grading system, oligodendrogliomas are classified as low grade (grade 2) or high grade (grade 3). […] Low-grade oligodendrogliomas are grade 2 tumours. They are slow growing and may be present for many years before they are diagnosed. […] Active surveillance with regular MRI scans may be done to watch for growth of the tumour if it cant be completely removed with surgery. […] Some clinical trials in Canada are open to people with oligodendroglioma. Clinical trials look at new ways to prevent, find and treat cancer.

• #1 Let’s Talk About Oligodendroglioma

  https://braintumor.org/news/lets-talk-about-oligodendroglioma/

  Since oligodendroglioma often affects younger individuals most commonly diagnosed in individuals between the ages of 35 and 44, according to the National Cancer Institute factors like career, family planning, and cognitive function play a significant role in treatment choices. […] Regardless of whether a patient decides to pursue treatment upfront or not, people living with oligodendroglioma typically undergo frequent medical imaging for the rest of their lives often at an interval of every 6-12 months. […] This watch and wait approach aims to preserve quality of life for as long as possible, delaying potential side effects from treatments like chemotherapy and radiation. […] In 2024, the U.S. Food and Drug Administration (FDA) approved vorasidenib for adults and pediatric patients (12+) with grade 2 astrocytoma or oligodendroglioma harboring an IDH1 or IDH2 mutation. This milestone marked the first-ever FDA-approved systemic therapy for these low-grade gliomas, offering patients a new option beyond traditional chemotherapy and radiation.

• #1 Astrocytoma and oligodendroglioma – Pathway

  https://m.pathway.md/diseases/astrocytoma-and-oligodendroglioma-recPgdA6WfDp0i1Lu

  The incidence of diffuse astrocytomas and oligodendrogliomas in the US is estimated at 0.44 and 0.23 per 100,000 person-year, respectively. […] Evaluation for recurrence: as per AANS/CNS 2025 guidelines, consider obtaining advanced imaging, such as MRS, perfusion-weighted imaging, DWI, or PET, to identify tumor recurrence or histologic progression in adult patients with suspected recurrence of histologically proven WHO grade 2 diffuse glioma.

• #1 Oligodendroglioma | UCSF Brain Tumor Center

  https://braintumorcenter.ucsf.edu/condition/oligodendroglioma

  Oligodendroglioma is relatively rare, accounting for about 1.4% of all primary brain tumors. In 2017, an estimated 670 new cases were diagnosed in the United States. Most oligodendrogliomas occur in adults, although can occasionally occur in infants and children as well. […] It is critical that all patients receive frequent monitoring by a neuro-oncologist for tumor recurrence or regrowth.

• #1 Oligodendrogliomas in pediatric and adult patients: an outcome-based study from the Surveillance, Epidemiology, and End Result database

  https://pmc.ncbi.nlm.nih.gov/articles/PMC5422333/

  The mean OS for all OG patients was 15.3 0.3 years. OS was significantly longer among the pediatric patients (30.3 1.1 years vs. 13.6 0.3 years, p0.001). […] Overall and cancer-specific mortalities among the pediatric patients (19.8% and 17.6%, respectively) were significantly lower than those in the adult patients (48.5% and 36.8%, p0.001). […] Cumulative 1-, 2-, and 5-year survival rates were significantly higher among the pediatric patients, compared to those in the adult patients (94%, 89%, and 85% for pediatric patients vs. 88%, 75%, and 66% for adult patients, p0.001). […] Surgical resection remains first-line therapy for OGs and is associated with significantly improved survival rates in all age groups, especially among children and adolescents. […] The extent of surgical resection can greatly affect quality of life and survival outcomes, with longer survival times achieved following gross total resection. […] Given the difficulty in achieving gross total resection and decreased PFS experienced with subtotal resection, adjuvant radiation has been utilized to improve local control. […] The authors report no conflicts of interest in this work.

• #1

  https://link.springer.com/article/10.1007/s11060-023-04368-6

  Since the introduction of the molecular definition of oligodendrogliomas based on isocitrate dehydrogenase (IDH)-status and the 1p19q-codeletion, it has become increasingly evident how this glioma entity differs much from other diffuse lower grade gliomas and stands out with longer survival and often better responsiveness to adjuvant therapy. […] The aim of this study was to describe the long-term course of the oligodendroglioma disease in a population-based setting and to determine which factors affect outcome in terms of survival. […] Individuals with molecularly defined oligodendrogliomas demonstrate long survival, also in a population-based setting. This is important to consider for optimal timing of therapies that may cause long-term side effects. Advanced age, large tumors and poor function before surgery are predictors of shorter survival.

• #1 Prognostic factors associated with survival in patients with anaplastic oligodendroglioma | PLOS One

  https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0211513

  Anaplastic oligodendroglioma is a rare disease with an inadequately understood prognosis. The aim of this study was to investigate factors associated with survival outcome in anaplastic oligodendroglioma patients. A population-based cohort study was conducted based on the Surveillance, Epidemiology, and End Results program. In total, 1899 patients with a histological diagnosis of anaplastic oligodendroglioma from 1973 to 2015 were included. […] The overall 1-, 3-, 5-, and 10-year survival of anaplastic oligodendroglioma was 78.7%, 60%, 50.2%, and 36.2%, respectively. Kaplan-Meier analysis indicated that age, marital status, presence of multiple primary malignancies, and surgical treatment were associated with overall survival, whereas sex and race were not. […] We therefore performed an analysis of AO patients in the population-based Surveillance, Epidemiology, and End Results (SEER) database. We intended to investigate the demographic characteristics of AO patients and discover factors associated with survival outcome.

• #1 Oligodendrogliomas in pediatric and adult patients: an outcome-based study from the Surveillance, Epidemiology, and End Result database

  https://pmc.ncbi.nlm.nih.gov/articles/PMC5422333/

  Pediatric patients had a lower overall mortality (19.8% vs. 48.5%) and lower cancer-specific mortality (17.6% vs. 36.8%). […] OGs most often present in Caucasian males in their fifth decade of life with tumors 4 cm in size. […] Children typically present with tumors in the temporal lobe, while adults present with tumors in the frontal lobe. […] Surgical resection confers a survival advantage among all patients, especially pediatric patients. […] Overall survival (OS) and cancer-specific survival are higher in the pediatric population. […] This study sought to examine a large cohort of pediatric and adult patients with OG from the Surveillance, Epidemiology, and End Results (SEER) database, in an effort to identify demographic, clinical, and treatment strategies that impact clinical outcomes.

• #1 Prognosis of Oligodendroglioma Patients Stratified by Age: A SEER Popu | IJGM

  https://www.dovepress.com/prognosis-of-oligodendroglioma-patients-stratified-by-age-a-seer-popul-peer-reviewed-fulltext-article-IJGM

  Glioma may affect patients of any age. So far, only a limited number of big data studies have been conducted concerning oligodendroglioma (OG) in diverse age groups. This study evaluated the risk factors for OG in different age groups using the Surveillance, Epidemiology, and End Results (SEER) database built by the National Cancer Institute, which is part of the National Institutes of Health. […] The all-cause mortality and the tumor-specific mortality increased with age. […] The older the age, the worse the survival would be. Thats, the mortality increased with age. In the clinic, healthcare professionals should be fully aware of the variability in the prognosis of OG patients in different age groups. Therefore, individualized treatments are recommended to OG patients in different age groups to optimize the prognosis.

• #1 Let’s Talk About Oligodendroglioma

  https://braintumor.org/news/lets-talk-about-oligodendroglioma/

  While oligodendroglioma is a relatively rare brain tumor, accounting for 1.2% of all primary brain tumors, an estimated 14,950 Americans are living with this tumor and navigating the unique challenges of this disease. […] Through the MyTumorID public health campaign, the National Brain Tumor Society (NBTS) is raising awareness about the importance of biomarker testing, which plays a crucial role in diagnosing and treating oligodendroglioma. Additionally, it helps inform patients and their loved ones about mutations that could open up future clinical trial options. […] Two key biomarkers define oligodendrogliomas. […] The 1p/19q chromosomal co-deletion is the loss of the short (p) arm of chromosome 1 and the long (q) arm of chromosome 19. This co-deletion is required for a definitive oligodendroglioma diagnosis.

• #1 Oligodendroglioma resection: a Surveillance, Epidemiology, and End Results (SEER) analysis in: Journal of Neurosurgery Volume 128 Issue 4 (2018) Journals

  https://thejns.org/view/journals/j-neurosurg/128/4/article-p1076.xml

  The available evidence suggests that the clinical benefits of extended resection are limited for chemosensitive tumors, such as primary CNS lymphoma. Oligodendroglioma is generally believed to be more sensitive to chemotherapy than astrocytoma of comparable grades. In this study the authors compare the survival benefit of gross-total resection (GTR) in patients with oligodendroglioma relative to patients with astrocytoma. […] Using the Surveillance, Epidemiology, and End Results (SEER) Program (19992010) database, the authors identified 2378 patients with WHO Grade II oligodendroglioma (O2 group) and 1028 patients with WHO Grade III oligodendroglioma (O3 group). Resection was defined as GTR, subtotal resection, biopsy only, or no resection. Kaplan-Meier and multivariate Cox regression survival analyses were used to assess survival with respect to extent of resection.

• #1 Let’s Talk About Oligodendroglioma

  https://braintumor.org/news/lets-talk-about-oligodendroglioma/

  Oligodendrogliomas can develop anywhere in the brain but commonly occur in the frontal and temporal lobes. […] According to the National Cancer Institute, seizures are the most frequent sign of the disease, and research published in CNS Oncology reports that seizures represent the first clinical symptom in 60% of cases or more, with epilepsy developing in 70-90% of oligodendroglioma cases. […] For people living with oligodendroglioma, routine MRIs and other medical scans are a necessary part of managing the disease. However, with each scan comes scanxiety the stress, worry, and emotional toll that can surface before, during, and after imaging. […] For young adults, living with oligodendroglioma presents a unique set of challenges. Oligodendrogliomas are frequently diagnosed between the ages of 35 and 44, an age range where many are focused on career advancement and raising children.

• #1 Surgery Insight: The Role of Surgery in the Management of Low-Grade Gliomas

  https://www.medscape.org/viewarticle/564764_2

  The phrase 'low-grade gliomas’ encompasses the entire spectrum of WHO grade I and II gliomas, which includes ependymomas, pilocytic astrocytomas, pleomorphic xanthoastrocytomas, diffuse astrocytomas, oligodendrogliomas, and mixed gliomas. […] Approximately 2,000 – 3,000 low-grade gliomas are diagnosed in the US every year, accounting for nearly 15% of all primary brain tumors. […] According to the Central Brain Tumor Registry of the United States (CBTRUS), the various histological classes of low-grade glioma have incidences varying between 0.10 and 0.46 per 100,000 people, and a cumulative incidence of approximately 0.9 per 100,000 people. […] Despite the preponderance of astrocytomas, there has been an apparent increase in recent years in the incidence of pure oligodendrogliomas and of mixed oligoastrocytomas.

• #1 Trends in clinico-epidemiology profile of surgically operated glioma patients in a tertiary care center over 12 years—through the looking glass! | Egyptian Journal of Neurosurgery | Full Text

  https://ejns.springeropen.com/articles/10.1186/s41984-021-00118-w

  Hospital-based cancer registries can provide information on the magnitude and distribution of cancers in a given hospital. […] Data were analyzed and compared with that of previously published literature, and inferences were drawn on patterns of reporting and epidemiology. […] Majority of cases (41.4%) were glioblastoma with the next common tumor (22.8%) being diffuse astrocytoma followed by pilocytic astrocytoma (6.2%) and oligodendroglioma (4.5%) in that order. […] The exact prevalence of these tumors in developing countries, especially in India, is difficult to determine due to lack of data registry like CBTRUS. […] Understanding the trend helps caregivers in early detection and management of glioma. […] The referral pattern suggests an increasing prevalence of glioma patients in the last 12 years. […] The study also highlights increasing tumor burden in developing country since the last decade with the trend of early age presentation.

• #1 Frontiers | Oligodendroglioma: A Review of Management and Pathways

  https://www.frontiersin.org/journals/molecular-neuroscience/articles/10.3389/fnmol.2021.722396/full

  Oligodendroglial tumors are rare tumors that constitute part of the neuro epithelial tumors of the central nervous system. Accounting to up to 5% of all neuroepithelial tumors (Ostrom et al., 2017), oligodendroglial tumors have an incidence rate of around 1,000 new cases per year in the United States. […] Alattar et al. (2018) conducted a Surveillance, Epidemiology, and End Results (SEER)-based analysis in 2017 and showed that GTR was not associated with improved survival in patients with WHO grade II and grade III oligodendrogliomas compared to patients with anaplastic astrocytomas and glioblastomas. […] The RTOG 9802 trial, which included non-molecularly stratified patients harboring grade II gliomas, demonstrated a 5.5-year survival benefit of PCV administration (Shaw et al., 2008). Results of this trial raise the possibility that the chemosensitivity seen in these tumors might be due to the IDH mutation that is common to both oligodendroglial and low-grade astrocytic gliomas. […] There are 11 ongoing clinical trials recruiting patients with AO. […] Lastly, it is worth noting that there are approximately 230 other clinical trials which involve oligodendrogliomas but are not actively recruiting patients.

• #1 Oligodendroglioma | Brain (and spinal cord) tumours | Cancer Research UK

  https://www.cancerresearchuk.org/about-cancer/brain-tumours/types/oligodendroglioma

  Oligodendrogliomas are rare. About 3 out of every 100 primary brain tumours (3%) diagnosed in England between 1995 and 2017 were oligodendrogliomas. […] Doctors are always trying to improve the diagnosis and treatment of brain tumours. As part of your treatment, your doctor might ask you to take part in a clinical trial. This might be to test a new treatment or look at different combinations of existing treatments.

• #1 Let’s Talk About Oligodendroglioma

  https://braintumor.org/news/lets-talk-about-oligodendroglioma/

  Since 2013, NBTS has funded more than $2 million in grants to 16 researchers across 12 different institutions, all benefitting oligodendroglioma and related low-grade glioma research. […] By pushing for federal research funding, directly supporting innovative research, and providing patient navigation and support, NBTS is driving progress on all fronts to bring better treatment options and improved quality of life to people living with oligodendroglioma.

• #2 Oligodendroglioma | Radiology Reference Article | Radiopaedia.org

  https://radiopaedia.org/articles/oligodendroglioma?embed_domain=hackmd.io%252F%2540yipuafecsl2jsu8smr5njq%252Fbnjhjgjghjghjghfavicon.icofavicon.ico&lang=us

  Oligodendroglioma is considered the third most common glioma accounting for 25% of primary brain tumors and 518% of all glial neoplasms. […] Oligodendrogliomas are usually tumors of middle-aged adults, occurring most commonly in the 4th and 5th decades of life, somewhat older for grade 3 tumors. There is a slight male predilection (M:F 1.3:1). […] They are rare in children.

• #2 Oligodendroglioma epidemiology and demographics – wikidoc

  https://www.wikidoc.org/index.php/Oligodendroglioma_epidemiology_and_demographics

  Oligodendroglioma, although rare, is the third most common glioma. In adults, it constitutes about 9.4% of all primary brain and central nervous system tumors and 5%18% of all glial neoplasms. The incidence of oligodendroglioma and anaplastic oligodendroglioma is estimated to be 0.32 and 0.17 cases per 100,000 individuals in the United States, respectively. Oligodendroglioma tends to affect the middle-aged adult population, most commonly occurring in the 4th and 5th decade of life. Median age at the time of diagnosis of oligodendroglioma is 35-47 years. Males are more commonly affected with oligodendroglioma than females with male to female ratio being approximately 1.3:1. Oligodendroglioma usually affects individuals of the Caucasian race. African American, Latin American, and Asian individuals are less likely to develop oligodendroglioma.

• #2 Oligodendroglioma – American Brain Tumor Association | Learn More

  https://www.abta.org/tumor_types/oligodendroglioma/

  Oligodendrogliomas are estimated to account for 1.3% of brain tumors in the United States with approximately 1,100 new diagnoses in the United States each year. […] Oligodendrogliomas are most common in adults and most often occur between the ages of 20-40. Although these tumors are found in both men and women, they tend to occur more often in men. Oligodendrogliomas are very rare in children under the age of 15. […] Regular MRI scans are recommended following the diagnosis of oligodendroglioma, generally at least once per year. Patients with seizures will need to be followed for their seizure medication.

• #2 Let’s Talk About Oligodendroglioma

  https://braintumor.org/news/lets-talk-about-oligodendroglioma/

  While oligodendroglioma is a relatively rare brain tumor, accounting for 1.2% of all primary brain tumors, an estimated 14,950 Americans are living with this tumor and navigating the unique challenges of this disease. […] Through the MyTumorID public health campaign, the National Brain Tumor Society (NBTS) is raising awareness about the importance of biomarker testing, which plays a crucial role in diagnosing and treating oligodendroglioma. Additionally, it helps inform patients and their loved ones about mutations that could open up future clinical trial options. […] Two key biomarkers define oligodendrogliomas. […] The 1p/19q chromosomal co-deletion is the loss of the short (p) arm of chromosome 1 and the long (q) arm of chromosome 19. This co-deletion is required for a definitive oligodendroglioma diagnosis.

• #2 Oligodendroglioma – Symptoms, Diagnosis, TreatmentSecond Opinion IconGroup 9Second Opinion IconGroup 49

  https://www.barrowneuro.org/condition/oligodendroglioma/

  Oligodendrogliomas account for less than two percent of brain tumors in the U.S., with approximately 1,100 new diagnoses each year. […] As of 2023, an estimated 15,000 people live with an oligodendroglioma in the U.S. […] While rare, oligodendrogliomas are more commonly diagnosed in adults and occur slightly more often in men than in women. […] Doctors diagnose most oligodendrogliomas in adults between 30 and 50. […] The average age at diagnosis for Grade 2 oligodendrogliomas is 43, and for Grade 3 oligodendrogliomas, it is 50. […] Most oligodendrogliomas are not inherited, but a family history of brain tumors or gliomas can slightly increase the overall risk. […] With regular treatment and monitoring, many people with oligodendrogliomas can live for years or even decades, especially those with low-grade tumors or favorable genetic markers.

• #2 Let’s Talk About Oligodendroglioma

  https://braintumor.org/news/lets-talk-about-oligodendroglioma/

  Since oligodendroglioma often affects younger individuals most commonly diagnosed in individuals between the ages of 35 and 44, according to the National Cancer Institute factors like career, family planning, and cognitive function play a significant role in treatment choices. […] Regardless of whether a patient decides to pursue treatment upfront or not, people living with oligodendroglioma typically undergo frequent medical imaging for the rest of their lives often at an interval of every 6-12 months. […] This watch and wait approach aims to preserve quality of life for as long as possible, delaying potential side effects from treatments like chemotherapy and radiation. […] In 2024, the U.S. Food and Drug Administration (FDA) approved vorasidenib for adults and pediatric patients (12+) with grade 2 astrocytoma or oligodendroglioma harboring an IDH1 or IDH2 mutation. This milestone marked the first-ever FDA-approved systemic therapy for these low-grade gliomas, offering patients a new option beyond traditional chemotherapy and radiation.

• #2 Oligodendrogliomas in pediatric and adult patients: an outcome-based study from the Surveillance, Epidemiology, and End Result database

  https://pmc.ncbi.nlm.nih.gov/articles/PMC5422333/

  Oligodendrogliomas (OGs) account for 20% of all intracranial tumors and 25% of gliomas. […] Data on 7,001 OG patients were abstracted from the Surveillance, Epidemiology, and End Result (SEER) database (19732013). […] Among 7,001 OG patients, 6.5% were pediatric (mean age 12 6 years), and 93.5% were adult (mean age 46 15 years). […] Overall, OGs were more common among males, with a male-to-female ratio of 1.28:1. […] Overall, OGs were more common among Caucasians (76.9%) and also among the African American (10.8% pediatric vs. 4.0% adult) and Hispanic (12.8% pediatric vs. 11.8% adult). […] Surgical resection was the primary treatment modality for both pediatric and adult populations (70.6% and 40.5%), followed by combined surgery and radiation (19.7% and 41.2%). […] Surgical resection was associated with significantly improved survival in both groups.

• #2 Oligodendroglioma | MedLink Neurology

  https://www.medlink.com/articles/oligodendroglioma

  Oligodendrogliomas are relatively rare. According to the Central Brain Tumor Registry of the United States (CBTRUS), the average age-adjusted annual incidence rate of oligodendroglioma is 0.30 for adults 40 years or older. Oligodendroglioma is rarer in children: the annual average age-adjusted incidence rate for patients younger than 15 years of age is 0.02% compared to 0.26% for patients aged 15 to 39 years. No patients younger than 40 years with oligodendroglioma WHO grade 3 were documented from 2016 to 2020 (44). It is highly likely that these epidemiologic numbers may shift as our registries catch up to the rapid changes observed in molecular neuropathology and their associated impact on the WHO classification system. […] Risk factors for glioma include inheritable genetic syndromes (such as Li-Fraumini, neurofibromatosis type 1, and Maffucci syndrome) and exposure to high-dose ionizing radiation, though no risk factors specific for oligodendroglioma are known; thus, no known preventative measures have been identified (38; 02).

• #2 Oligodendroglioma – Symptoms, Diagnosis, TreatmentSecond Opinion IconGroup 9Second Opinion IconGroup 49

  https://www.barrowneuro.org/condition/oligodendroglioma/

  As a whole, the five-year survival rate for oligodendrogliomas is 79.5 percent. […] For Grade 2 oligodendrogliomas, the five- to 10-year survival rate can be as high as 90 percent with optimal treatment and ideal genetic factors. […] The prognosis for Grade 3 oligodendrogliomas varies more, with five-year survival rates between 30 and 50 percent, depending on the response to treatment and genetic factors. […] Currently, there is no known way to prevent oligodendrogliomas from developing. […] Some cases are linked to rare genetic conditions, like neurofibromatosis type I (NF1) and Li-Fraumeni Syndrome, which increases the risk of some brain tumors, including oligodendrogliomas. […] Advances in genetic research may one day help identify additional oligodendroglioma risk factors.

• #2 Oligodendroglioma | UCSF Brain Tumor Center

  https://braintumorcenter.ucsf.edu/condition/oligodendroglioma

  Oligodendroglioma is relatively rare, accounting for about 1.4% of all primary brain tumors. In 2017, an estimated 670 new cases were diagnosed in the United States. Most oligodendrogliomas occur in adults, although can occasionally occur in infants and children as well. […] It is critical that all patients receive frequent monitoring by a neuro-oncologist for tumor recurrence or regrowth.

• #2 Oligodendroglioma | Canadian Cancer Society

  https://cancer.ca/en/cancer-information/cancer-types/brain-and-spinal-cord/what-is-a-brain-or-spinal-cord-tumour/oligodendroglioma

  Oligodendrogliomas are a type of glioma that starts in glial cells called oligodendrocytes. Oligodendroglioma sometimes spreads to the cerebrospinal fluid but rarely spreads outside the brain or spinal cord. Based on the World Health Organization (WHO) grading system, oligodendrogliomas are classified as low grade (grade 2) or high grade (grade 3). […] Low-grade oligodendrogliomas are grade 2 tumours. They are slow growing and may be present for many years before they are diagnosed. […] Active surveillance with regular MRI scans may be done to watch for growth of the tumour if it cant be completely removed with surgery. […] Some clinical trials in Canada are open to people with oligodendroglioma. Clinical trials look at new ways to prevent, find and treat cancer.

• #2 Oligodendroglioma – VALINTERMED treatment in Valencia

  https://valintermed.com/en/medlibrary/oligodendroglioma-2/

  According to statistics, oligodendrogliomas account for about 5-10% of all gliomas and 1-2% of all brain tumors. These tumors are most common in adults aged 30 to 50 years and are slightly more common in men than in women. According to the journal Neuro-Oncology, the incidence of oligodendrogliomas in the United States is 0.4-0.5 cases per 100,000 people per year. In European countries, the rates are similar. It is also noted that oligodendrogliomas are more often diagnosed in people with a genetic predisposition, in particular, in those who have hereditary syndromes, including Li-Fraumeni syndrome and neurofibromatosis type 2. […] Monitoring of patients with oligodendrogliomas includes regular follow-up examinations with MRI to assess possible disease progression or recurrence. Prognosis depends on a number of factors, including the grade of malignancy and the presence of specific genetic mutations. In general, 5-year survival for low-grade oligodendrogliomas is up to 80%, while for high-grade forms it is lower and is about 20-30%. Complications after treatment may include neurological deficits and adverse reactions to chemotherapy, which requires careful rehabilitation.

• #2 Oligodendroglioma: Symptoms, Treatment & Prognosis

  https://my.clevelandclinic.org/health/diseases/21191-oligodendroglioma

  Like all tumors or cancers, oligodendroglioma can be fatal. But oligodendroglioma generally has higher survival rates than other gliomas and brain cancers. The chances of prolonged survival are higher with lower-grade tumors. Other factors can also play a role, so your healthcare provider can tell you more about the outlook for your specific case.

• #2 Oligodendroglioma and Other IDH-Mutated Tumors: Diagnosis and Treatment – NCI

  https://www.cancer.gov/rare-brain-spine-tumor/tumors/oligodendroglioma

  Oligodendrogliomas occur in people of any age but are most common in those between the ages of 35 and 44. They occur more often in males and are rare in children. They are most common in non-Hispanic white people. An estimated 14,950 people are living with this tumor in the United States. […] The relative five-year survival rate for oligodendroglioma is 79.5 percent. However, many factors affect prognosis. These include the tumor grade and molecular type, the persons age and health when diagnosed, and how they respond to treatment. If you want to understand your prognosis, talk to your doctor.

• #2 Oligodendrogliomas in pediatric and adult patients: an outcome-based s | CMAR

  https://www.dovepress.com/oligodendrogliomas-in-pediatric-and-adult-patients-an-outcome-based-st-peer-reviewed-fulltext-article-CMAR

  The mean OS for all OG patients was 15.3 ± 0.3 years. OS was significantly longer among the pediatric patients (30.3 ± 1.1 years vs. 13.6 ± 0.3 years, p<0.001). [...] Overall and cancer-specific mortalities among the pediatric patients (19.8% and 17.6%, respectively) were significantly lower than those in the adult patients (48.5% and 36.8%, p<0.001). [...] Cumulative 1-, 2-, and 5-year survival rates were significantly higher among the pediatric patients, compared to those in the adult patients (94%, 89%, and 85% for pediatric patients vs. 88%, 75%, and 66% for adult patients, p<0.001). [...] Surgical resection remains first-line therapy for OGs and is associated with significantly improved survival rates in all age groups, especially among children and adolescents. [...] The extent of surgical resection can greatly affect quality of life and survival outcomes, with longer survival times achieved following gross total resection.

• #2

  https://link.springer.com/article/10.1007/s11060-023-04368-6

  In this population based multi-center observational study with long-term data of WHO grade 2 oligodendrogliomas, the median survival was almost 18 years. […] This long-term study of patient with heterogeneously treated 1p19q-codeleted oligodendroglioma WHO grade 2 demonstrates that the median survival approaches 20 years in a population-based setting. Further, increased patient age, lower functional status and larger preoperative tumor size were independently associated with impaired survival.

• #2 Oligodendrogliomas in pediatric and adult patients: an outcome-based study from the Surveillance, Epidemiology, and End Result database

  https://pmc.ncbi.nlm.nih.gov/articles/PMC5422333/

  The mean OS for all OG patients was 15.3 0.3 years. OS was significantly longer among the pediatric patients (30.3 1.1 years vs. 13.6 0.3 years, p0.001). […] Overall and cancer-specific mortalities among the pediatric patients (19.8% and 17.6%, respectively) were significantly lower than those in the adult patients (48.5% and 36.8%, p0.001). […] Cumulative 1-, 2-, and 5-year survival rates were significantly higher among the pediatric patients, compared to those in the adult patients (94%, 89%, and 85% for pediatric patients vs. 88%, 75%, and 66% for adult patients, p0.001). […] Surgical resection remains first-line therapy for OGs and is associated with significantly improved survival rates in all age groups, especially among children and adolescents. […] The extent of surgical resection can greatly affect quality of life and survival outcomes, with longer survival times achieved following gross total resection. […] Given the difficulty in achieving gross total resection and decreased PFS experienced with subtotal resection, adjuvant radiation has been utilized to improve local control. […] The authors report no conflicts of interest in this work.

• #2 Prognosis of Oligodendroglioma Patients Stratified by Age: A SEER Popu | IJGM

  https://www.dovepress.com/prognosis-of-oligodendroglioma-patients-stratified-by-age-a-seer-popul-peer-reviewed-fulltext-article-IJGM

  Population-based studies have shown that the incidence of glioma varies across different age groups. […] Our study supported this viewpoint, as the univariate and multivariate analyses showed that both the all-cause mortality and tumor-specific mortality increased noticeably with age in the seven age groups. Individualized treatments are recommended for OG patients to achieve better outcomes. […] The correlation between age and survival of OG patients was confirmed based on the SEER database. The older the age, the worse the survival would be. Thats to say, the mortality increased with age. In the clinic, healthcare professionals should be fully aware of the variability in the prognosis of OG patients in different age groups. An individualized treatment is recommended for OG patients. It is not possible to distinguish oligodendrogliomas based on children, adults, and the elderly, but to develop diagnosis and treatment plans based on more detailed age groups.

• #2

  https://link.springer.com/article/10.1007/s11060-023-04368-6

  Since the introduction of the molecular definition of oligodendrogliomas based on isocitrate dehydrogenase (IDH)-status and the 1p19q-codeletion, it has become increasingly evident how this glioma entity differs much from other diffuse lower grade gliomas and stands out with longer survival and often better responsiveness to adjuvant therapy. […] The aim of this study was to describe the long-term course of the oligodendroglioma disease in a population-based setting and to determine which factors affect outcome in terms of survival. […] Individuals with molecularly defined oligodendrogliomas demonstrate long survival, also in a population-based setting. This is important to consider for optimal timing of therapies that may cause long-term side effects. Advanced age, large tumors and poor function before surgery are predictors of shorter survival.

• #2 Treatment and prognosis of IDH-mutant, 1p/19q-codeleted oligodendrogliomas in adults – UpToDate

  https://www.uptodate.com/contents/treatment-and-prognosis-of-idh-mutant-1p-19q-codeleted-oligodendrogliomas-in-adults

  Oligodendroglial tumors constitute approximately 5 to 10 percent of all glial tumors. Oligodendroglial tumors typically arise in the fourth to sixth decades, with low-grade tumors occurring at an earlier age than anaplastic tumors. Despite the prolonged clinical course seen with oligodendroglial tumors, they are almost always life limiting. […] According to the WHO classification for central nervous system tumors, the diagnosis of an oligodendroglioma requires the presence of both an isocitrate dehydrogenase (IDH) mutation and combined 1p/19q loss. […] The treatment and prognosis of grade 2 and 3 IDH-mutant, 1p/19q-codeleted oligodendrogliomas will be reviewed here.

• #2 Prognostic factors associated with survival in patients with anaplastic oligodendroglioma | PLOS One

  https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0211513

  The prognosis of coexistence of malignant tumors of different histologic types is unclear at present. Our research is the first study to find that coexistence of AO and other malignancy predicts shorter survival in AO patients. […] In this study, we analyzed a population-based dataset to investigate the demographic characteristics and prognostic factors of a rare disease. We demonstrated that older age, single marital status, and presence of multiple primary malignancies were independently associated with worse survival outcome, whereas surgery was associated with prolonged survival of patients with AO.

• #2 Oligodendrogliomas in pediatric and adult patients: an outcome-based s | CMAR

  https://www.dovepress.com/oligodendrogliomas-in-pediatric-and-adult-patients-an-outcome-based-st-peer-reviewed-fulltext-article-CMAR

  Surgical resection was associated with significantly improved survival in both groups. […] Pediatric patients had a lower overall mortality (19.8% vs. 48.5%) and lower cancer-specific mortality (17.6% vs. 36.8%). […] OGs most often present in Caucasian males in their fifth decade of life with tumors 4 cm in size. […] Children typically present with tumors in the temporal lobe, while adults present with tumors in the frontal lobe. […] Surgical resection confers a survival advantage among all patients, especially pediatric patients. […] Overall survival (OS) and cancer-specific survival are higher in the pediatric population. […] This study sought to examine a large cohort of pediatric and adult patients with OG from the Surveillance, Epidemiology, and End Results (SEER) database, in an effort to identify demographic, clinical, and treatment strategies that impact clinical outcomes.

• #2 Oligodendrogliomas in pediatric and adult patients: an outcome-based s | CMAR

  https://www.dovepress.com/oligodendrogliomas-in-pediatric-and-adult-patients-an-outcome-based-st-peer-reviewed-fulltext-article-CMAR

  Oligodendrogliomas (OGs) account for 20% of all intracranial tumors and 25% of gliomas. […] This study examines a large cohort of OG patients in an effort to define the demographic, clinical, and pathologic factors associated with clinical and survival outcomes. […] Data on 7,001 OG patients were abstracted from the Surveillance, Epidemiology, and End Result (SEER) database (1973-2013). […] Among 7,001 OG patients, 6.5% were pediatric (mean age 12 ± 6 years), and 93.5% were adult (mean age 46 ± 15 years). […] Overall, OGs were more common among males, with a male-to-female ratio of 1.28:1. […] Overall, OGs were more common among Caucasians (76.9%) and also among the African American (10.8% pediatric vs. 4.0% adult) and Hispanic (12.8% pediatric vs. 11.8% adult). […] Surgical resection was the primary treatment modality for both pediatric and adult populations (70.6% and 40.5%), followed by combined surgery and radiation (19.7% and 41.2%).

• #2 Oligodendroglioma resection: a Surveillance, Epidemiology, and End Results (SEER) analysis in: Journal of Neurosurgery Volume 128 Issue 4 (2018) Journals

  https://thejns.org/view/journals/j-neurosurg/128/4/article-p1076.xml

  A comprehensive search of the published literature identified 8 articles without compelling evidence that GTR is associated with improved overall survival in patients with oligodendroglioma. […] This SEER-based analysis and review of the literature suggest that GTR is not associated with improved survival in patients with oligodendroglioma. This finding contrasts with the documented association between GTR and overall survival in anaplastic astrocytoma and glioblastoma. The authors suggest that this difference may reflect the sensitivity of oligodendroglioma to chemotherapy as compared with astrocytomas.

• #2 Let’s Talk About Oligodendroglioma

  https://braintumor.org/news/lets-talk-about-oligodendroglioma/

  Since 2013, NBTS has funded more than $2 million in grants to 16 researchers across 12 different institutions, all benefitting oligodendroglioma and related low-grade glioma research. […] By pushing for federal research funding, directly supporting innovative research, and providing patient navigation and support, NBTS is driving progress on all fronts to bring better treatment options and improved quality of life to people living with oligodendroglioma.

• #2 Trends in clinico-epidemiology profile of surgically operated glioma patients in a tertiary care center over 12 years—through the looking glass! | Egyptian Journal of Neurosurgery | Full Text

  https://ejns.springeropen.com/articles/10.1186/s41984-021-00118-w

  Hospital-based cancer registries can provide information on the magnitude and distribution of cancers in a given hospital. […] Data were analyzed and compared with that of previously published literature, and inferences were drawn on patterns of reporting and epidemiology. […] Majority of cases (41.4%) were glioblastoma with the next common tumor (22.8%) being diffuse astrocytoma followed by pilocytic astrocytoma (6.2%) and oligodendroglioma (4.5%) in that order. […] The exact prevalence of these tumors in developing countries, especially in India, is difficult to determine due to lack of data registry like CBTRUS. […] Understanding the trend helps caregivers in early detection and management of glioma. […] The referral pattern suggests an increasing prevalence of glioma patients in the last 12 years. […] The study also highlights increasing tumor burden in developing country since the last decade with the trend of early age presentation.

• #2 First IDH Inhibitor for Astrocytomas and Oligodendrogliomas | Research | AACR

  https://www.aacr.org/patients-caregivers/progress-against-cancer/first-idh-inhibitor-for-astrocytomas-and-oligodendrogliomas/

  In recent decades, grade 1-3 astrocytomas accounted for 18.8% of gliomas diagnosed in the United States, while oligodendrogliomas accounted for approximately 10.7%. […] The FDA rendered its decision on August 6, 2024.

• #3 Oligodendroglioma | Concise Medical Knowledge

  https://www.lecturio.com/concepts/oligodendroglioma/

  Oligodendrogliomas are the 3rd most common CNS tumor. […] Incidence: 3rd most common primary brain neoplasm (behind glioblastoma multiforme and low-grade diffuse astrocytoma). […] Accounts for approximately 5% of primary CNS tumors. […] Approximately 1000 patients diagnosed with oligodendrogliomas each year in the United States. […] Median age at diagnosis: 25-45 years. […] Slightly more common in males than in females.

• #3 Oligodendrogliomas in pediatric and adult patients: an outcome-based s | CMAR

  https://www.dovepress.com/oligodendrogliomas-in-pediatric-and-adult-patients-an-outcome-based-st-peer-reviewed-fulltext-article-CMAR

  Oligodendrogliomas (OGs) account for 20% of all intracranial tumors and 25% of gliomas. […] This study examines a large cohort of OG patients in an effort to define the demographic, clinical, and pathologic factors associated with clinical and survival outcomes. […] Data on 7,001 OG patients were abstracted from the Surveillance, Epidemiology, and End Result (SEER) database (1973-2013). […] Among 7,001 OG patients, 6.5% were pediatric (mean age 12 ± 6 years), and 93.5% were adult (mean age 46 ± 15 years). […] Overall, OGs were more common among males, with a male-to-female ratio of 1.28:1. […] Overall, OGs were more common among Caucasians (76.9%) and also among the African American (10.8% pediatric vs. 4.0% adult) and Hispanic (12.8% pediatric vs. 11.8% adult). […] Surgical resection was the primary treatment modality for both pediatric and adult populations (70.6% and 40.5%), followed by combined surgery and radiation (19.7% and 41.2%).

• #3 Oligodendroglioma – Symptoms, Diagnosis, TreatmentSecond Opinion IconGroup 9Second Opinion IconGroup 49

  https://www.barrowneuro.org/condition/oligodendroglioma/

  Oligodendrogliomas account for less than two percent of brain tumors in the U.S., with approximately 1,100 new diagnoses each year. […] As of 2023, an estimated 15,000 people live with an oligodendroglioma in the U.S. […] While rare, oligodendrogliomas are more commonly diagnosed in adults and occur slightly more often in men than in women. […] Doctors diagnose most oligodendrogliomas in adults between 30 and 50. […] The average age at diagnosis for Grade 2 oligodendrogliomas is 43, and for Grade 3 oligodendrogliomas, it is 50. […] Most oligodendrogliomas are not inherited, but a family history of brain tumors or gliomas can slightly increase the overall risk. […] With regular treatment and monitoring, many people with oligodendrogliomas can live for years or even decades, especially those with low-grade tumors or favorable genetic markers.

• #3 Oligodendrogliomas in pediatric and adult patients: an outcome-based s | CMAR

  https://www.dovepress.com/oligodendrogliomas-in-pediatric-and-adult-patients-an-outcome-based-st-peer-reviewed-fulltext-article-CMAR

  Surgical resection was associated with significantly improved survival in both groups. […] Pediatric patients had a lower overall mortality (19.8% vs. 48.5%) and lower cancer-specific mortality (17.6% vs. 36.8%). […] OGs most often present in Caucasian males in their fifth decade of life with tumors 4 cm in size. […] Children typically present with tumors in the temporal lobe, while adults present with tumors in the frontal lobe. […] Surgical resection confers a survival advantage among all patients, especially pediatric patients. […] Overall survival (OS) and cancer-specific survival are higher in the pediatric population. […] This study sought to examine a large cohort of pediatric and adult patients with OG from the Surveillance, Epidemiology, and End Results (SEER) database, in an effort to identify demographic, clinical, and treatment strategies that impact clinical outcomes.

• #3 Prognostic factors associated with survival in patients with anaplastic oligodendroglioma | PLOS One

  https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0211513

  The prognosis of coexistence of malignant tumors of different histologic types is unclear at present. Our research is the first study to find that coexistence of AO and other malignancy predicts shorter survival in AO patients. […] In this study, we analyzed a population-based dataset to investigate the demographic characteristics and prognostic factors of a rare disease. We demonstrated that older age, single marital status, and presence of multiple primary malignancies were independently associated with worse survival outcome, whereas surgery was associated with prolonged survival of patients with AO.

• #3 Prognosis of Oligodendroglioma Patients Stratified by Age: A SEER Popu | IJGM

  https://www.dovepress.com/prognosis-of-oligodendroglioma-patients-stratified-by-age-a-seer-popul-peer-reviewed-fulltext-article-IJGM

  Population-based studies have shown that the incidence of glioma varies across different age groups. […] Our study supported this viewpoint, as the univariate and multivariate analyses showed that both the all-cause mortality and tumor-specific mortality increased noticeably with age in the seven age groups. Individualized treatments are recommended for OG patients to achieve better outcomes. […] The correlation between age and survival of OG patients was confirmed based on the SEER database. The older the age, the worse the survival would be. Thats to say, the mortality increased with age. In the clinic, healthcare professionals should be fully aware of the variability in the prognosis of OG patients in different age groups. An individualized treatment is recommended for OG patients. It is not possible to distinguish oligodendrogliomas based on children, adults, and the elderly, but to develop diagnosis and treatment plans based on more detailed age groups.

• #3 Frontiers | Oligodendroglioma: A Review of Management and Pathways

  https://www.frontiersin.org/journals/molecular-neuroscience/articles/10.3389/fnmol.2021.722396/full

  Oligodendroglial tumors are rare tumors that constitute part of the neuro epithelial tumors of the central nervous system. Accounting to up to 5% of all neuroepithelial tumors (Ostrom et al., 2017), oligodendroglial tumors have an incidence rate of around 1,000 new cases per year in the United States. […] Alattar et al. (2018) conducted a Surveillance, Epidemiology, and End Results (SEER)-based analysis in 2017 and showed that GTR was not associated with improved survival in patients with WHO grade II and grade III oligodendrogliomas compared to patients with anaplastic astrocytomas and glioblastomas. […] The RTOG 9802 trial, which included non-molecularly stratified patients harboring grade II gliomas, demonstrated a 5.5-year survival benefit of PCV administration (Shaw et al., 2008). Results of this trial raise the possibility that the chemosensitivity seen in these tumors might be due to the IDH mutation that is common to both oligodendroglial and low-grade astrocytic gliomas. […] There are 11 ongoing clinical trials recruiting patients with AO. […] Lastly, it is worth noting that there are approximately 230 other clinical trials which involve oligodendrogliomas but are not actively recruiting patients.

• #3 Oligodendroglioma | Canadian Cancer Society

  https://cancer.ca/en/cancer-information/cancer-types/brain-and-spinal-cord/what-is-a-brain-or-spinal-cord-tumour/oligodendroglioma

  Oligodendrogliomas are a type of glioma that starts in glial cells called oligodendrocytes. Oligodendroglioma sometimes spreads to the cerebrospinal fluid but rarely spreads outside the brain or spinal cord. Based on the World Health Organization (WHO) grading system, oligodendrogliomas are classified as low grade (grade 2) or high grade (grade 3). […] Low-grade oligodendrogliomas are grade 2 tumours. They are slow growing and may be present for many years before they are diagnosed. […] Active surveillance with regular MRI scans may be done to watch for growth of the tumour if it cant be completely removed with surgery. […] Some clinical trials in Canada are open to people with oligodendroglioma. Clinical trials look at new ways to prevent, find and treat cancer.

• #4 Oligodendrogliomas in pediatric and adult patients: an outcome-based s | CMAR

  https://www.dovepress.com/oligodendrogliomas-in-pediatric-and-adult-patients-an-outcome-based-st-peer-reviewed-fulltext-article-CMAR

  The mean OS for all OG patients was 15.3 ± 0.3 years. OS was significantly longer among the pediatric patients (30.3 ± 1.1 years vs. 13.6 ± 0.3 years, p<0.001). [...] Overall and cancer-specific mortalities among the pediatric patients (19.8% and 17.6%, respectively) were significantly lower than those in the adult patients (48.5% and 36.8%, p<0.001). [...] Cumulative 1-, 2-, and 5-year survival rates were significantly higher among the pediatric patients, compared to those in the adult patients (94%, 89%, and 85% for pediatric patients vs. 88%, 75%, and 66% for adult patients, p<0.001). [...] Surgical resection remains first-line therapy for OGs and is associated with significantly improved survival rates in all age groups, especially among children and adolescents. [...] The extent of surgical resection can greatly affect quality of life and survival outcomes, with longer survival times achieved following gross total resection.

Zobacz więcej